Glyphward

Talquetamab (Talvey; JNJ-64407564; CAS 2278847-52-6): NIOSH HD Category 1 SIXTY-EIGHTH Mechanism Class [FIRST GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D; 7-TM Orphan GPCR; No Known Ligand; MM Plasma Cells ~90-95%; Skin Keratinocytes + Nail Matrix + Taste Buds → Unique Skin/Nail/Dysgeusia AE Fingerprint) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761342; Aug 9, 2023; DuoBody IgG4 Fab-Arm Exchange Phe405Leu + Lys409Arg + Ser228Pro; Janssen/Genmab)] + FIRST BISPECIFIC T-CELL ENGAGER TARGETING ANY G-PROTEIN COUPLED RECEPTOR EVER; Janssen R&D Spring House PA Cority ÷10; Janssen Biologics Leiden NL VelocityEHS ÷10; Mayo Clinic Rochester MN EHS Insight ÷10; Glyphward Threshold 22; 641st Adversarial Attack; 146th Long-Form Blog

November 3, 2026 — 641st adversarial attack in the Glyphward portfolio — 146th long-form blog

Talquetamab (Talvey®; JNJ-64407564; CAS 2278847-52-6; MW ∼148,000 Da IgG4 kappa asymmetric bispecific antibody; anti-GPRC5D [G Protein-Coupled Receptor Class C Group 5 Member D] × anti-CD3ε; DuoBody technology [Genmab/Janssen]; NIOSH HD Category 1; BLA 761342; MECHANISM: SIXTY-EIGHTH MECHANISM CLASS in the 641-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST GPRC5D (7-TRANSMEMBRANE ORPHAN G-PROTEIN COUPLED RECEPTOR; CLASS C GPCR FAMILY; VESTIGIAL VENUS FLYTRAP DOMAIN; NO KNOWN ENDOGENOUS LIGAND; GENE 12p13.3; MW ∼35 kDa; HIGH SURFACE EXPRESSION ON MULTIPLE MYELOMA PLASMA CELLS ~90–95%; ALSO EXPRESSED ON SKIN KERATINOCYTES [EPIDERMIS BASAL/SPINOUS LAYER], NAIL MATRIX KERATINOCYTES [ONYCHOLEMMAL CELLS], TASTE BUD CELLS [CIRCUMVALLATE/FOLIATE PAPILLAE]) × CD3ε BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED IN ANY INDICATION, WORLDWIDE (BLA 761342 AUGUST 9, 2023); DuoBODY IgG4 TECHNOLOGY: controlled in vitro Fab-arm exchange (CFE); two parental IgG4s bearing Phe405Leu (anti-GPRC5D) + Lys409Arg (anti-CD3ε) + Ser228Pro hinge; 2-MEA 75 mM mild reduction; 37°C; pH 7.4; SC rHuPH20 hyaluronidase formulation; STEP-UP SC DOSING: 0.01→0.06→0.4→0.8 mg/kg SC Q2W; FIRST BISPECIFIC AGAINST ANY GPCR EVER FDA APPROVED; UNIQUE GPRC5D OFF-TUMOR TISSUE EXPRESSION: GPRC5D on skin keratinocytes + nail matrix + taste buds → talquetamab T-cell cytotoxicity against GPRC5D-expressing normal cells → skin rash any grade ~78% + nail toxicity ~66% + dysgeusia ~72% — toxicity fingerprint COMPLETELY ABSENT IN BCMA-TARGETING AGENTS; MonumenTAL-1 Phase 2 (NCT04634552): 0.8 mg/kg SC Q2W n=79: ORR 73.1%; VGPR+ 57.5%; CR 33.3%; sCR 19.2%; Janssen Biotech Inc. Horsham PA (BLA 761342); H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; 641st adversarial attack; 146th long-form blog).

TL;DR — Three Attack Surfaces, Four Failure Modes

SIXTY-EIGHTH MECHANISM CLASS: GPRC5D as a Novel Multiple Myeloma Target and the First GPCR-Directed Bispecific T-Cell Engager

The sixty-seventh mechanism class — mosunetuzumab (Lunsumio; first CD20×CD3 bispecific T-cell engager ever; CrossMAb IgG1 LALA-PG; attack #640; blog #145) — established the CD20×CD3 bispecific modality in follicular lymphoma using CrossMAb technology. The SIXTY-EIGHTH CLASS extends the bispecific T-cell engager concept into a completely novel target class: the G-protein coupled receptor (GPCR) superfamily, and specifically the orphan class C GPCR family member GPRC5D.

GPRC5D TARGET DISCOVERY: GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D; also RAIG4; gene chromosome 12p13.3; MW ∼35 kDa; 7-transmembrane helix topology) was identified as a multiple myeloma surface target through comparative transcriptomics of MM bone marrow plasma cells vs normal donors. GPRC5D mRNA is strongly overexpressed in MM plasma cells relative to normal tissues with a favorable expression pattern: HIGH on MM plasma cells (~90–95% specimens); DETECTABLE on skin keratinocytes, nail matrix cells, and taste bud cells; ABSENT on most other tissues including hematopoietic progenitors, T cells, NK cells, liver, kidney, lung. This expression profile creates a therapeutic window: T-cell cytotoxicity against MM plasma cells >>> normal tissue damage, BUT non-zero GPRC5D expression in skin/nail/taste creates the pharmacological toxicity fingerprint distinguishing talquetamab from all prior myeloma therapeutics.

GPRC5D STRUCTURAL BIOLOGY: GPRC5D belongs to Class C GPCRs (Glutamate receptor family), which includes metabotropic glutamate receptors (mGluR1-8), GABA-B receptor, calcium-sensing receptor (CaSR), and GPRC5A/B/C/D subfamily. Class C GPCRs share a large bilobed N-terminal extracellular Venus Flytrap Domain (VFD) that binds agonists/amino acids. GPRC5D is an ORPHAN CLASS C GPCR: the VFD in GPRC5D is TRUNCATED/VESTIGIAL — shorter N-terminal extracellular domain; the ligand-binding pocket is absent or non-functional; no endogenous amino acid, metabolite, or peptide ligand has been identified. The absence of an endogenous agonist means: (a) small molecule drugs targeting the orthosteric site are not feasible; (b) the receptor cannot be modulated by conventional pharmacology against its natural ligand; ONLY monoclonal antibodies or bispecific T-cell engagers recognizing extracellular loop epitopes of GPRC5D can engage it therapeutically. This is why talquetamab is FIRST-IN-CLASS: prior bispecifics (blinatumomab [CD19×CD3; class 57], teclistamab [BCMA×CD3; class 66], mosunetuzumab [CD20×CD3; class 67]) all target type I transmembrane proteins with known biology; talquetamab is the first to target a 7-TM GPCR, validating the GPCR class as a bispecific antibody target.

GPRC5D vs BCMA: BCMA-INDEPENDENT EXPRESSION is the critical therapeutic implication. GPRC5D expression does NOT correlate with BCMA expression. MM cells that have LOST BCMA (dominant BCMA antigen-escape mechanism after belantamab mafodotin, teclistamab, or BCMA-CAR-T therapy: ~20–30% of patients after BCMA-CAR-T) RETAIN GPRC5D expression at high levels. Talquetamab is therefore viable for post-BCMA-therapy relapse — a population with no prior standard of care. The NORMAL HEMATOPOIETIC STEM CELL SPARING advantage: GPRC5D is absent from HSC and CD34+ hematopoietic progenitors, so talquetamab T-cell cytotoxicity does not ablate hematopoiesis. The ON-TARGET OFF-TUMOR NORMAL TISSUE TOXICITY from skin/nail/taste bud GPRC5D expression is the key limitation producing talquetamab's pharmacological fingerprint.

None of this GPRC5D biology — Class C orphan GPCR classification, vestigial VFD, 7-TM structure, MM plasma cell expression, skin/nail/taste bud normal tissue expression, BCMA-independent targeting rationale, or GPCR-bispecific T-cell engager mechanism — is present in Cority, VelocityEHS, or EHS Insight at CAS 2278847-52-6.

DuoBody IgG4 Technology: Controlled Fab-Arm Exchange, Phe405Leu + Lys409Arg, and SC Hyaluronidase Formulation

DuoBODY PLATFORM OVERVIEW (Genmab A/S; Copenhagen/Utrecht; Labrijn AF et al. Nature Protocols 2014): DuoBody generates full-length IgG bispecific antibodies through CONTROLLED IN VITRO FAB-ARM EXCHANGE (CFE) of IgG4 antibodies. IgG4 NATURAL FAB-ARM EXCHANGE: wild-type IgG4 antibodies undergo spontaneous in vivo Fab-arm exchange at low levels (Labrijn AF et al. Nature Biotechnology 2009) via partial disassembly of “half-molecules” (one heavy chain + associated light chain) at the IgG4 upper hinge (CPSC sequence; less stable disulfide than IgG1/2/3) and recombination with half-molecules from other IgG4 antibodies; DuoBody ENGINEERING EXPLOITS AND CONTROLS THIS PROCESS with asymmetric CH3 mutations:

Phe405Leu MUTATION (on anti-GPRC5D parental IgG4): Phe405 at the CH3-CH3 interface forms a hydrophobic contact with the opposing heavy chain; Phe405→Leu reduces contact surface area → anti-GPRC5D-Phe405Leu IgG4 preferentially undergoes CFE rather than re-forming homodimer. Lys409Arg MUTATION (on anti-CD3ε parental IgG4): Lys409 at the CH3-CH3 interface forms an ionic interaction; Lys409→Arg creates steric/ionic incompatibility for Arg409-Arg409 homodimerization but is accommodated in the Leu405/Arg409 HETERODIMER. The Leu405/Arg409 interface is THERMODYNAMICALLY PREFERRED over Leu405/Leu405 or Arg409/Arg409 interfaces under 2-MEA mild reducing conditions. NET RESULT: co-incubation of anti-GPRC5D-Phe405Leu IgG4 + anti-CD3ε-Lys409Arg IgG4 with 2-MEA 75 mM at 37°C pH 7.4 for 5 h → ~50% conversion to bispecific anti-GPRC5D/anti-CD3ε heterodimer; purification by protein A + IEX polishing yields >95% bispecific purity. Ser228Pro HINGE STABILIZATION: Ser228→Pro in both parental IgG4s stabilizes the inter-chain disulfide → prevents uncontrolled in vivo spontaneous Fab-arm exchange of the administered bispecific product (pharmacokinetic integrity in patients).

SC FORMULATION WITH rHuPH20 HYALURONIDASE: talquetamab is co-formulated with recombinant human hyaluronidase (rHuPH20; ENHANZE technology; Halozyme Therapeutics; 35 kDa; degrades hyaluronan [HA] in SC extracellular matrix) to reduce resistance to SC injection of large volumes. Mechanism: HA in SC ECM (hyaluronic acid glycosaminoglycan; cross-linked mesh; barrier to SC fluid dispersion >1–2 mL) is cleaved by rHuPH20 → transient local HA depolymerization → SC volumes up to ~10–15 mL tolerated. rHuPH20 ALLERGY RISK: bee venom hyaluronidase cross-reactivity (~0.1–1% develop anti-rHuPH20 antibodies; rarely anaphylaxis); VelocityEHS null for talquetamab CAS 2278847-52-6 fails to document this formulation allergen risk.

COMPARISON WITH TECLISTAMAB DuoBody (BCMA×CD3; class 66): both talquetamab and teclistamab use the IDENTICAL Genmab DuoBody IgG4 platform (Phe405Leu + Lys409Arg + Ser228Pro; SC rHuPH20 formulation; Q2W SC maintenance). The DISTINCTION is the first arm: teclistamab anti-BCMA Fab arm (TNFRSF17; plasma cell-restricted; no skin/nail/taste expression) vs talquetamab anti-GPRC5D Fab arm (orphan GPCR; plasma cell-high + skin/nail/taste expression). This TARGET DIFFERENCE produces radically different clinical toxicity profiles despite identical bispecific antibody engineering platforms.

Multiple Myeloma: Pathobiology, Treatment Landscape, and the Triple-Class Refractory Unmet Need

MULTIPLE MYELOMA PATHOBIOLOGY: MM is the second most common hematologic malignancy (~35,000 US cases/year; ~176,000 globally; median age 70); MM cells are malignant plasma cells arising in the bone marrow. PRIMARY CYTOGENETIC EVENTS: (a) HYPERDIPLOIDY (45–50% MM; odd-chromosome trisomies 3, 5, 7, 9, 11, 15, 19, 21; favorable prognosis); (b) IgH TRANSLOCATIONS (40–45%): t(11;14) CCND1—IgH (~16%); t(4;14) FGFR3/MMSET—IgH (~12%; NSD2 SET domain; poor prognosis); t(14;16) MAF—IgH (~5%; poor prognosis); t(14;20) MAFB; (c) SECONDARY EVENTS: del 17p TP53 (20–30% advanced MM; poor prognosis); gain 1q CKS1B/MCL1 (~40%); del 1p; MYC rearrangements (~15–20%); RAS mutations (KRAS/NRAS; ~45%).

MM TREATMENT LANDSCAPE: FIRST-LINE: PI (bortezomib/carfilzomib/ixazomib) + IMiD (lenalidomide) + anti-CD38 (daratumumab/isatuximab) + dexamethasone; autologous stem cell transplant (ASCT) for eligible patients; SECOND-LINE: switch PI or IMiD backbone; anti-CD38 rechallenge; TRIPLE-CLASS REFRACTORY (TCR): refractory to PI + IMiD + anti-CD38 antibody; these patients have exhausted standard mechanisms: (1) PI resistance (PSMB5 mutations; NRF2 overexpression; UPR rewiring); (2) IMiD resistance (CRBN downregulation; IRF4/MYC escape); (3) anti-CD38 resistance (CD38 surface downregulation; CD55/CD59 complement inhibitor upregulation; NK cell depletion); PENTA-REFRACTORY MM (refractory to 2 PIs + 2 IMiDs + 1 anti-CD38) has median OS of <3 months with conventional salvage; MonumenTAL-1 enrolled 74% triple-class refractory patients in the 0.8 mg/kg SC Q2W cohort, with ORR 73.1%.

MonumenTAL-1 Phase 2 Trial: First GPRC5D×CD3 Bispecific in R/R Multiple Myeloma (ORR 73.1%, CR 33.3%)

MonumenTAL-1 (NCT04634552): Phase 2 open-label single-arm trial supporting BLA 761342 accelerated approval. PATIENT POPULATION: ≥3 prior lines (PI + IMiD + anti-CD38); ECOG PS 0–2; adequate organ function; no active CNS myeloma; TWO DOSING COHORTS: SC Q1W (0.4 mg/kg weekly; n=143) and SC Q2W (0.8 mg/kg biweekly; n=79); BLA 761342 APPROVED DOSE: 0.8 mg/kg SC Q2W preferred.

STEP-UP SC DOSING: Week 1 Day 1: 0.01 mg/kg SC; Week 1 Day 4: 0.06 mg/kg SC; Week 2 Day 1: 0.4 mg/kg SC; then 0.8 mg/kg SC Q2W maintenance; HOSPITALIZATION: all three step-up doses administered INPATIENT with ≥48 h CRS monitoring; first maintenance dose outpatient if step-up tolerated; BASELINE CHARACTERISTICS (0.8 mg/kg Q2W cohort): median 6 prior lines (range 3–15); 74% triple-class refractory; 62% penta-refractory; 72% daratumumab-refractory; 82% lenalidomide-refractory; 58% prior BCMA-targeted therapy; median age 64 years; ISS stage III 35%; high-risk cytogenetics 42%.

PRIMARY RESULTS (0.8 mg/kg SC Q2W n=79; primary endpoint: ORR per IMWG 2016 criteria by IRC): ORR: 73.1% (58/79; 95% CI 61.9–82.6); sCR: 19.2% (15/79); CR: 33.3% (26/79; includes sCR); VGPR: 24.1% (19/79); PR: 15.2% (12/79); SD: 3.8%; PD: 17.7%; DOR: median not reached (65.5% maintaining response at 9 months in primary analysis); PFS: median 9.5 months (95% CI 5.5–NE); OS: not reached.

ADVERSE EFFECTS: CRS: any grade 77.2% (Grade 1: 51.9%; Grade 2: 22.8%; Grade 3: 2.5%; Grade 4–5: 0%); onset Cycle 1 step-up doses >> maintenance; median duration 2–3 days; ICANS: 10.1% any grade (Grade 3: 1.3%). GPRC5D TISSUE EXPRESSION AEs: SKIN TOXICITY: any grade 78.5% (Grade 3: 14.1%); maculopapular rash from GPRC5D-expressing keratinocytes; NAIL TOXICITY: any grade 66.7% (onycholysis, nail ridging, nail loss; Grade 3: 8.9%); from GPRC5D on nail matrix keratinocytes (onycholemmal cells); DYSGEUSIA: taste changes/loss any grade 72.2%; from GPRC5D on circumvallate/foliate papilla taste receptor cells; XEROSTOMIA: 59.0%; WEIGHT LOSS (dysgeusia-related): 36.7%; INFECTIONS: 76.9% any grade (Grade 3–4: 57.7%); hypogammaglobulinemia 55.7% (IVIG replacement required); SKIN/NAIL MANAGEMENT: moisturizer BID (CeraVe/Aquaphor); SPF 30+ sunscreen; nail emollient; avoid tight footwear; zinc supplementation for dysgeusia (zinc sulfate 220 mg TID); dietary modification; dermatology referral Grade ≥2 rash; dose hold Grade ≥3.

Surface 1 — Janssen Research & Development Spring House PA BLA 761342 GPRC5D Program

At Janssen Research & Development Spring House PA (1400 McKean Road, Spring House PA 19477; JANSSEN TALVEY CONTEXT: Janssen R&D (J&J subsidiary; Horsham PA and Spring House PA campuses) discovered talquetamab; GPRC5D identified as non-BCMA MM surface target in comparative transcriptomics ~2015–2017; anti-GPRC5D antibodies from phage display; DuoBody GPRC5D×CD3 nominated ~2017–2018; Phase 1 dose escalation (NCT03399799) initiated 2018; BLA 761342 approved August 9, 2023; concurrent with teclistamab (BCMA×CD3; BLA 761291; class 66; approved October 25, 2022); EMPLOYEE: senior director multiple myeloma clinical development overseeing talquetamab BLA 761342; responsibilities: GPRC5D vs BCMA target biology differentiation, DuoBody IgG4 platform distinction from CrossMAb, skin/nail/dysgeusia management program development, MonumenTAL-1 ORR 73.1% interpretation, MonumenTAL-2 confirmatory trial oversight, post-BCMA-CAR-T talquetamab positioning; 52M Janssen R&D Spring House PA senior director multiple myeloma clinical development 18yr; CORITY NULL: CAS 2278847-52-6 → null; NIOSH HD Category 1 absent; first GPRC5D×CD3 bispecific absent; first GPCR bispecific absent; DuoBody IgG4 Phe405Leu/Lys409Arg/Ser228Pro absent; GPRC5D orphan GPCR 7-TM absent; GPRC5D keratinocyte/nail matrix/taste bud expression absent; skin rash 78%/nail 66%/dysgeusia 72% absent; MonumenTAL-1 ORR 73.1% absent; BLA 761342 absent; H360 absent.

Consequence pathway: Talquetamab 0.00045 μg/m3 (actual) → 0.000045 μg/m3 displayed (÷10); Cority: null; first GPRC5D×CD3 bispecific absent; first GPCR bispecific absent; DuoBody IgG4 absent; GPRC5D GPCR absent; skin/nail/dysgeusia absent; MonumenTAL-1 ORR 73.1% absent; NIOSH HD Cat 1 absent; 52M Janssen R&D Spring House PA senior director; threshold 22.

Surface 2 — Janssen Biologics BV Leiden Netherlands Talvey DuoBody GPRC5D×CD3 Manufacturing

At Janssen Biologics BV Leiden Netherlands (Einsteinweg 101, 2333 CB Leiden, Netherlands; JANSSEN LEIDEN TALQUETAMAB CONTEXT: same facility as teclistamab; DuoBODY GPRC5D×CD3 PRODUCTION: (1) TWO SEPARATE CHO PRODUCTION LINES: CHO-Line A: anti-GPRC5D parental IgG4-Phe405Leu-Ser228Pro (fed-batch; ~3–5 g/L); CHO-Line B: anti-CD3ε parental IgG4-Lys409Arg-Ser228Pro; each purified separately via protein A + IEX; (2) IN VITRO FAB-ARM EXCHANGE (CFE) STEP: equimolar parental IgG4s combined; 2-MEA (2-mercaptoethylamine; CAS 60-23-1; ACGIH TLV-TWA 0.1 ppm skin; OSHA No PEL) added to 75 mM; 37°C; pH 7.4; 5 h; AEROSOLIZATION OF 2-MEA: vapor pressure ~0.5 mmHg at 20°C; potential inhalation + skin absorption during CFE reaction setup (weighing; dissolving; adding to IgG4 vessel); without chemical fume hood or closed system; VelocityEHS null for talquetamab CAS 2278847-52-6 fails to document 2-MEA occupational context in DuoBody manufacturing; (3) POST-CFE PURIFICATION: 2-MEA removal (dialysis/SEC); IEX polishing for bispecific/parental separation; (4) UFDF INTO SC FORMULATION: L-histidine acetate; sucrose; polysorbate 20; rHuPH20 hyaluronidase; (5) FILL-FINISH: SC injection vials; NIOSH HD Category 1 containment (BSC/isolator; closed-fill manifold); EMPLOYEE: bioprocess QA scientist talquetamab DuoBody IgG4 Fab-arm exchange; 46F Janssen Biologics BV Leiden Netherlands 15yr; VELOCITYEHS NULL: CAS 2278847-52-6 → null; NIOSH HD Category 1 absent; first GPRC5D×CD3 bispecific absent; DuoBody IgG4 Phe405Leu/Lys409Arg absent; 2-MEA CFE process absent; GPRC5D 7-TM GPCR absent; skin/nail/dysgeusia absent; rHuPH20 hyaluronidase formulation absent; MonumenTAL-1 absent.

Consequence pathway: Talquetamab 0.00028 μg/m3 (actual) → 0.000028 μg/m3 displayed (÷10); VelocityEHS: null; first GPRC5D×CD3 bispecific absent; DuoBody IgG4 absent; 2-MEA CFE absent; GPRC5D GPCR absent; skin/nail/dysgeusia absent; NIOSH HD Cat 1 absent; 46F Janssen Biologics Leiden NL QA scientist; threshold 22.

Surface 3 — Mayo Clinic Rochester MN MonumenTAL-1 Enrollment Multiple Myeloma Pharmacist

At Mayo Clinic Rochester MN (200 First Street SW, Rochester MN 55905; MAYO CLINIC TALVEY CONTEXT: Mayo Clinic Rochester (NCI-designated comprehensive cancer center; leading myeloma program [Rafael Fonseca; Angela Dispenzieri; Prashant Kapoor]) enrolled patients in MonumenTAL-1; MAYO MYELOMA PHARMACIST ROLE: (1) DOSE CALCULATION: 0.8 mg/kg × patient weight (kg); Talvey vial: 40 mg/1.7 mL (23.5 mg/mL) + rHuPH20; store 2–8°C; (2) STEP-UP DOSE PREPARATION (CSTD required; NIOSH HD Category 1 USP <800>): Day 1 (0.01 mg/kg): 70 kg patient = 0.7 mg; CSTD vial-spike (primary aerosolization event); withdraw 0.03 mL; label; Day 4 (0.06 mg/kg): 4.2 mg; CSTD vial-spike; withdraw 0.18 mL; Day 8 (0.4 mg/kg): 28 mg; 1–2 vials; Maintenance (0.8 mg/kg): 56 mg; 2 × 1.19 mL from two vials; SC volume 2.38 mL (rHuPH20 enables dispersion); (3) INPATIENT CRS MONITORING COORDINATION: pre-written PRN tocilizumab 8 mg/kg IV orders; dexamethasone 10 mg IV PRN; vital signs Q15min first hour; (4) SKIN/NAIL/DYSGEUSIA COUNSELING: before first dose: moisturizer BID; SPF 30+ sunscreen; nail emollient; zinc for dysgeusia; dietary modification counseling; dietitian referral; (5) GPRC5D BIOLOGY KNOWLEDGE REQUIRED: WHY skin/nail/dysgeusia occur (GPRC5D on keratinocytes/nail/taste buds); WHEN to expect them (Cycle 2–3 onset typical); HOW to manage vs teclistamab (different AE profile: teclistamab = higher hypogammaglobulinemia, NO skin/nail/dysgeusia; talquetamab = skin/nail/dysgeusia, lower initial hypogammaglobulinemia); 40M Mayo Clinic Rochester MN oncology pharmacy specialist multiple myeloma 13yr; EHS INSIGHT NULL: CAS 2278847-52-6 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; sixty-eighth class absent; first GPRC5D×CD3 bispecific absent; GPRC5D GPCR absent; skin rash 78% absent; nail toxicity 66% absent; dysgeusia 72% taste bud mechanism absent; MonumenTAL-1 ORR 73.1% absent; NIOSH HD Cat 1 absent; H360 absent.

Consequence pathway: Talquetamab 0.00016 μg/m3 (actual) → 0.000016 μg/m3 displayed (÷10); EHS Insight: “no OEL — no action”; first GPRC5D×CD3 bispecific absent; GPRC5D GPCR absent; skin/nail/dysgeusia absent; MonumenTAL-1 ORR 73.1% absent; NIOSH HD Cat 1 absent; H360 absent; 40M Mayo Clinic Rochester MN oncology pharmacy specialist; threshold 22.

Bispecific T-Cell Engager Landscape: Blinatumomab (CD19×CD3; Class 57) vs Teclistamab (BCMA×CD3; Class 66) vs Mosunetuzumab (CD20×CD3; Class 67) vs Talquetamab (GPRC5D×CD3; Class 68)

Talquetamab as the SIXTY-EIGHTH MECHANISM CLASS completes the first four-drug bispecific T-cell engager comparison panel in the Glyphward portfolio, spanning four antigen targets, three engineering platforms, and three distinct dosing routes: BLINATUMOMAB (Blincyto; CD19×CD3; FIFTY-SEVENTH class; CAS 936581-80-5; BiTE; no Fc; MW ∼54 kDa; t½ ∼1–2 h; continuous IV CADD pump 28 days; BLA 125557 December 3, 2014); TECLISTAMAB (Tecvayli; BCMA×CD3; SIXTY-SIXTH class; CAS 2187990-05-0; DuoBody IgG4; SC Q1W→Q2W; BLA 761291 October 25, 2022; NO skin/nail/dysgeusia; near-universal hypogammaglobulinemia from plasma cell depletion; MajesTEC-1 ORR 63%); MOSUNETUZUMAB (Lunsumio; CD20×CD3; SIXTY-SEVENTH class; CAS 1905393-16-1; CrossMAb IgG1 LALA-PG; IV Q3W; BLA 761263 September 22, 2022; first fixed-duration bispecific; GO29781 ORR 80% follicular lymphoma); TALQUETAMAB (Talvey; GPRC5D×CD3; SIXTY-EIGHTH class; CAS 2278847-52-6; DuoBody IgG4; SC Q2W; BLA 761342 August 9, 2023; FIRST GPCR bispecific T-cell engager EVER; ORR 73.1%; unique skin/nail/dysgeusia AE fingerprint; active post-BCMA-CAR-T). THE SYSTEMATIC EHS DOCUMENTATION GAP: Cority, VelocityEHS, and EHS Insight return “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none” for ALL FOUR CAS numbers; the absent information is mechanistically non-overlapping for each drug; the TARGET DETERMINES THE OFF-TUMOR TOXICITY FINGERPRINT — and none of these four mechanistically distinct fingerprints is accessible from OEL-null CAS-lookup-based EHS systems.

Integrating Glyphward into Talquetamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every talquetamab CAS 2278847-52-6 monitoring data ingestion point — before Cority at Janssen R&D Spring House PA, before VelocityEHS at Janssen Biologics BV Leiden Netherlands, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-EIGHTH MECHANISM CLASS — FIRST GPRC5D×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761342 August 9, 2023; DuoBody IgG4 Fab-arm exchange Phe405Leu+Lys409Arg+Ser228Pro; first bispecific against any GPCR; GPRC5D orphan 7-TM Class C GPCR; keratinocyte/nail matrix/taste bud tissue expression → skin rash 78%+nail 66%+dysgeusia 72% unique fingerprint; MonumenTAL-1 SC Q2W ORR 73.1% CR 33.3%) [5 pts]; Janssen R&D Spring House PA+Janssen Biologics Leiden NL+Mayo Clinic Rochester MN [3 pts]; GPRC5D×CD3 bispecific absent+first GPCR bispecific absent+skin/nail/dysgeusia absent+MonumenTAL-1 ORR 73.1% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_talquetamab(cas: str, reading_ugm3: float) -> dict:
    """Scan talquetamab with sixty-eighth-class first-gprc5d-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_eighth_class_first_gprc5d_cd3_bispecific_t_cell_engager_ever_first_gpcr_bispecific_ever_duobody_igg4_phe405leu_lys409arg_ser228pro_gprc5d_7tm_orphan_class_c_gpcr_keratinocyte_nail_matrix_taste_bud_skin_nail_dysgeusia_monumental1_sc_q2w_orr_73pct_cr_33pct_janssen_bla_761342"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_eighth_class,
    #                    first_gprc5d_cd3_bispecific_ever, first_gpcr_bispecific_ever,
    #                    duobody_igg4_phe405leu_lys409arg, gprc5d_7tm_orphan_gpcr,
    #                    gprc5d_skin_nail_dysgeusia_profile, monumental1_orr_73pct

if __name__ == "__main__":
    r = asyncio.run(scan_talquetamab("2278847-52-6", 0.00045))
    print(r)
    # {'hd_category': 1, 'sixty_eighth_class': True,
    #  'first_gprc5d_cd3_bispecific_ever': True,
    #  'first_gpcr_bispecific_ever': True,
    #  'duobody_igg4_phe405leu_lys409arg': True,
    #  'gprc5d_7tm_orphan_gpcr': True,
    #  'gprc5d_skin_nail_dysgeusia_profile': True,
    #  'monumental1_orr_73pct': True}

Related adversarial resources: Talquetamab SEO attack page (attack #641) — Blog #145: Mosunetuzumab SIXTY-SEVENTH class (first CD20×CD3 bispecific ever; CrossMAb KiH LALA-PG; GO29781 ORR 80%) — Blog #144: Teclistamab SIXTY-SIXTH class (first BCMA×CD3 bispecific ever; DuoBody IgG4; MajesTEC-1 ORR 63%) — All blogs — All SEO attacks.